Thus further understanding of the mechanism by which Rac1 modulates the interaction between LEF-1 and β-catenin may provide an alternative therapeutic avenue to reduce β-catenin–LEF-1 signaling in colorectal cancer. Here, RAC1 is linked to colorectal cancer.